Mechanistically, αKG treatment decreases H3K4me1 in the promoter regions of B2M, thus upregulating MHC‐I expression and enhancing CTLs‐mediated anti‐tumor effects in multiple types of cancer including RCC. This evidence concerns the gene B2M and cancer.